** Shares of telehealth firm WW International WW.O rise 8.5% to $41.50 premarket
** Co, also known as WeightWatchers, reports its clinical subscription revenue rose 55.1% during the quarter ended June 30, driven by compounded semaglutide subscriptions
** Says from May 22, it began transitioning subscribers from compounded semaglutide to FDA-approved medications, in line with current FDA guidance
** Co, forecasts 2025 total revenue to be in the range of $685 million to $700 million
** Forecasts adj. core profit to be in the range of $140 million to $150 million
** Co has not previously provided a forecast for 2025
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。